FIG. 5.

Pathway enrichment analysis of (a) combined phosphoproteomic analysis following EGFR ASO 16, 18, and 21 treatment compared with standard ASO control (STD) in PC9 cells reveals inhibition of cell cycle and transcription and upregulation of apoptosis and EGFR (Erbb1) downstream pathways. Comparable pathway enrichment was observed following (b) direct inhibition of EGFR using erlotinib treated relative to STD. Analysis was performed using the DE proteins. Figures represent pathways that are formed only using upregulated DE proteins (red) and downregulated DE proteins (blue). All pathways were selected based on negative log10 P values >10.